ProCE Banner Activity

ELECTRA and ELEVATE: Elacestrant Combinations for ER+/HER2- Advanced/Metastatic Breast Cancer

Conference Coverage
Slideset

ELECTRA and ELEVATE data suggested that multiple elacestrant combinations were safe for patients with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine therapy plus CDK4/6 inhibition. Clinically meaningful efficacy with elacestrant plus abemaciclib was seen regardless of ESR1 mutation status.

Released: December 17, 2024

Expiration: June 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation